US firm Vical will carry out a phase 1 clinical trial of its Vaxfectin-formulated DNA vaccine for A/H1N1 pandemic swine flu influenza for the US Navy.
Free Buyers Guide
Leading Guide to Submarine and Submersible Suppliers for the Naval Industry
Thank you.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Your download email will arrive shortly. Please check your mail inbox to download the buyer's guide
You may also be interested in:
The funds will be provided by the navy through the Henry M Jackson Foundation for the Advancement of Military Medicine.
The investigational new drug application describing the trial design was approved by the US Food and Drug Administration in 2009.
According to the company, the navy funding builds on the success of our H5N1 vaccine, expand the safety and immunogenicity database for Vaxfectin-formulated vaccines in humans, and open the door to broader collaborations with the US Government.
Free Buyers Guide
Leading Guide to Submarine and Submersible Suppliers for the Naval Industry
Thank you.
Your download email will arrive shortly. Please check your mail inbox to download the buyer's guide
You may also be interested in:
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Naval Technology Excellence Awards - The Benefits of Entering
Gain the recognition you deserve! The Naval Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving industry advancements. Don’t miss your chance to stand out—submit your entry today!
Nominate Now
